Selventa is currently seeking diagnostic discovery and development partners. We seek partnerships to deliver a disease-specific TDx or a drug-specific CDx. We are currently focused on developing diagnostics for autoimmune/inflammatory diseases such as rheumatoid arthritis, Crohn’s disease, ulcerative colitis, and in oncology for complex mechanisms such as angiogenesis.
Selventa offers flexible forms of collaboration. We welcome the opportunity to discuss potential partnerships with:
- Pharmaceutical and biotechnology companies
- Diagnostic companies
- Clinical research organizations
- Patient registries to access blood and tissue samples, and molecular patient data
- Academic and Government affiliated clinical organizations
Selventa is a biomarker discovery company that enables personalized healthcare. Selventa's expertise include analyzing large-scale molecular patient data to discover and refine biomarker panels for diagnostic co-development. Selventa is actively seeking development and validation partners for both CDx and TDx opportunities.